Duality Biotherapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	1,941	1,787
Revenue Growth (YoY)	8.66%	-
Cost of Revenue	1,157	427.66
Gross Profit	784.67	1,359
Selling, General & Admin	158.69	62.57
Research & Development	815.38	559
Other Operating Expenses	-2.36	1.06
Operating Expenses	971.71	622.62
Operating Income	-187.04	736.27
Interest Expense	-0.25	-0.19
Interest & Investment Income	48.11	34.48
Currency Exchange Gain (Loss)	12.27	41.94
Other Non Operating Income (Expenses)	-873.42	-1,018
EBT Excluding Unusual Items	-1,000	-205.4
Asset Writedown	-21.35	-
Other Unusual Items	7.12	3.15
Pretax Income	-1,015	-202.25
Income Tax Expense	35.89	155.26
Net Income	-1,050	-357.51
Net Income to Common	-1,050	-357.51
Shares Outstanding (Basic)	8	8
Shares Outstanding (Diluted)	8	8
EPS (Basic)	-131.30	-44.69
EPS (Diluted)	-131.30	-44.69
Free Cash Flow	281.7	805.05
Free Cash Flow Per Share	35.21	100.63
Gross Margin	40.42%	76.06%
Operating Margin	-9.63%	41.21%
Profit Margin	-54.11%	-20.01%
Free Cash Flow Margin	14.51%	45.06%
EBITDA	-183.72	737.75
EBITDA Margin	-9.46%	41.30%
D&A For EBITDA	3.32	1.48
EBIT	-187.04	736.27
EBIT Margin	-9.63%	41.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.